Facebook
Twitter
LinkedIn
ForwardMiami Cancer Institute Multispecialty Grand Rounds: Ablative Therapy for Oligometastatic Disease – Where are we now and where are we going?
The oligometastatic state is a proposed stage between localized cancer and widely metastatic disease, comprising an intermediate subset of metastatic cancer patients.
During this conference, Daniel Gomez, M.D., will discuss the future directions, including randomized trials that explore the role of ablative therapy in oligometastatic disease.
Target Audience
Oncologists, Radiation Oncologists, Hematology Oncologists, Radiation Therapists, General Surgeons, General Practitioners, Obstetricians and Gynecologists, Nurses, Pharmacists, Respiratory Therapists, Patient Navigators and all other interested healthcare professionals.
Learning Objectives
- Define the various stages of oligometastatic disease and the biologic implications of each.
- Analyze the current oligometastatic literature and the rationale for ablative therapy.
- Summarize future directions, including randomized trials,that explore the role of ablative therapy in oligometastatic disease.
Daniel Gomez, M.D., MBA
Director of Thoracic Radiation Oncology and
Vice Chair of Clinical Operations
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
New York, New York
Daniel Gomez, M.D., faculty for this educational activity, is a researcher for Varian, AstraZeneca and Merck. He is a consultant for GRAIL, Olympus, Medtronic, and Johnson and Johnson; and a speaker for MedLearning Group. He has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.
Guilherme Rabinowits, M.D., conference series director, has indicated that he is an advisor with Sanofi-Genzyme, Regeneron, Castle and Boston Gene. All of the relevant financial relationships listed for this individual have been mitigated.
Michael Chuong, M.D., moderator, has indicated that he is a researcher with ViewRay, Novocure and AstraZeneca. He is a consultant with ViewRay. He is an advisor with ViewRay and Advanced Accelerator Applications. He is a speaker for ViewRay, Elekta and Sirtex. All of the relevant financial relationships listed for this individual have been mitigated.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationship(s) to disclose with ineligible companies*
*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 1 credit hour, CE Broker Course #20-680158, by the Florida Boards of Medicine, Osteopathic Medicine and by the Florida Council of Physician Assistants.
This activity has also been approved for 1 credit hour for Nurse Practitioners, Nurses, Pharmacists and Techs and Respiratory Therapists. Baptist Health South Florida CE Broker Provider #50-182.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 General certificate of attendance
- 1.00 Nurse Practitioners
- 1.00 Florida Board of Nursing
- 1.00 Florida Board of Pharmacy
- 1.00 Florida Board of Respiratory Therapy
Required Hardware/Software
 | PC/Mac UsersThis site is supported on the most recent stable releases of the following browsers:
| ||||||
 | Mobile UsersThis site is supported on the following mobile devices:
| ||||||
 | Technical SupportIf you are experiencing technical difficulties or have received an error message, please send an email to [email protected] and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours. |
